尼日利亚乔斯地区1型人类免疫缺陷病毒感染儿童的预处理及获得性耐药性
Pretreatment and Acquired Drug Resistance in Children With Human Immunodeficiency Virus Type 1 in Jos, Nigeria.
作者信息
Ebonyi Augustine O, Okpokwu Jonathan, Rawizza Holly, Chebu Philippe, Chaplin Beth, Hamel Donald, Oguche Stephen, Agbaji Oche O, Sagay Atiene S, Kanki Phyllis J, Imade Godwin E
机构信息
Department of Paediatrics, University of Jos, Jos University Teaching Hospital, Jos, Nigeria.
AIDS Prevention Initiative in Nigeria-supported ISO 15189 Laboratory, Jos University Teaching Hospital, Jos, Nigeria.
出版信息
Open Forum Infect Dis. 2024 Feb 19;11(3):ofae092. doi: 10.1093/ofid/ofae092. eCollection 2024 Mar.
We determined pretreatment and acquired human immunodeficiency virus (HIV) drug resistance among children with HIV type 1 (HIV-1) in Jos, Nigeria. The majority (71%) of those who failed first-line antiretroviral therapy were on a nevirapine-containing regimen. The prevalence of pretreatment (48%) and acquired (76%) HIV drug resistance mutations was high in our study. Wider access to HIV drug resistance testing after treatment failure is necessary to optimize second-line treatment options among children with HIV in Nigeria.
我们确定了尼日利亚乔斯市1型人类免疫缺陷病毒（HIV-1）感染儿童的治疗前及获得性人类免疫缺陷病毒（HIV）耐药情况。一线抗逆转录病毒治疗失败的患者中，大多数（71%）采用了含奈韦拉平的治疗方案。在我们的研究中，治疗前HIV耐药突变的患病率（48%）和获得性HIV耐药突变的患病率（76%）都很高。治疗失败后更广泛地开展HIV耐药检测，对于优化尼日利亚HIV感染儿童的二线治疗方案很有必要。
Zotero 插件